Breaking News
Global News
Chola Securities in News
Sessions News
Economy News
Nifty 50
Sensex
Nifty Bank
Bankex
Nifty 100
BSE Sensex 50
Nifty Financial Services
BSE Sensex Next 50
Nifty Midcap 100
BSE Bharat 22
Nasdaq
DJIA
S&P 500
Hang Seng
Nikkei 225
Straits Times
FTSE 100
KLSE Composite
Jakarta Composite
Exchange Holiday List
Historical Returns
Top Gainers
Top Losers
52 Week High
52 Week Low
Most Active by Value
Most Active by Volume
Out Performer
Under Performer
Advances & Declines
Only Buyers and Sellers
Bulk deal
Block deal
Nifty Futures
Nifty Options
Bank Nifty Futures
Bank Nifty Options
Stock Futures
Stock Options
Increase in OI
Decrease in OI
Highest in OI
Lowest in OI
All Index Futures
Most Active Contracts
Most Active Call
Most Active Put
Solutions
Platforms
Research
More
Markets
Become a partner
The company clarified that GMBU e.V. and its affiliates are not related to the promoter, promoter group, or group companies of Novelix Pharmaceuticals. The transaction does not fall under related-party transactions, and no promoter or promoter group entity has any interest in the agreement.
Novelix Pharmaceuticals is engaged in business of trading of pharmaceuticals and related products and is into the business of trading of shares and securities. The companys; consolidated net profit surged 405.56% to Rs 0.91 crore on 20.76% jump in revenue from operations to Rs 25.19 crore in Q4 FY26 over Q4 FY25.
The counter rallied 3.28% to end at Rs 54.40 n the BSE.
Powered by Capital Market - Live News
on Chola Securities Mobile & Web App.
Stay organised, informed & in control while accessing your portfolio, reports, trading tools and service requests—all in one seamless platform.